MedElevator
Войти в исследования European journal of haematology · 2025
Efficacy and Safety of Bendamustine-Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Robin Alexander, Owen Carolyn, Perry Sarah, Street Lesley, Chua Neil, Stewart Douglas, Puckrin Robert
Аннотация
INTRODUCTION: Bendamustine-rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B-cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B-cell (Hodgkin) lymphoma (NLPBL).
METHODS: This retrospective, population-based study included consecutive patients ≥ 18 years old who received BR for NLPBL in Alberta, Canada.
RESULTS: The study population comprised 23 patients with a median age of 39 years (range 18-74) who received BR for treatment-naive (n = 17) or relapsed/refractory (n = 6) NLPBL. Advanced stage disease was present in 18 (78%), splenic involvement in 9 (39%), and bone marrow involvement in 8 (35%) patients. The response rate to BR was 100%, with a complete response in 78% and a partial response in 22%. After a median follow-up of 4.3 years (range 0.8-9.0), the 4-year progression-free survival and overall survival rates were 83% (95% CI: 55%-94%) and 87% (95% CI: 58%-97%) for all patients and 84% (95% CI: 50%-96%) and 91% (95% CI: 51%-99%) for recipients of first-line BR, respectively. The safety profile was in keeping with the known toxicities of BR, with the most common adverse events consisting of neutropenia, rash, and infusion reactions.
CONCLUSION: These findings suggest that BR is a promising treatment option for NLPBL, with a favorable efficacy and safety profile.
METHODS: This retrospective, population-based study included consecutive patients ≥ 18 years old who received BR for NLPBL in Alberta, Canada.
RESULTS: The study population comprised 23 patients with a median age of 39 years (range 18-74) who received BR for treatment-naive (n = 17) or relapsed/refractory (n = 6) NLPBL. Advanced stage disease was present in 18 (78%), splenic involvement in 9 (39%), and bone marrow involvement in 8 (35%) patients. The response rate to BR was 100%, with a complete response in 78% and a partial response in 22%. After a median follow-up of 4.3 years (range 0.8-9.0), the 4-year progression-free survival and overall survival rates were 83% (95% CI: 55%-94%) and 87% (95% CI: 58%-97%) for all patients and 84% (95% CI: 50%-96%) and 91% (95% CI: 51%-99%) for recipients of first-line BR, respectively. The safety profile was in keeping with the known toxicities of BR, with the most common adverse events consisting of neutropenia, rash, and infusion reactions.
CONCLUSION: These findings suggest that BR is a promising treatment option for NLPBL, with a favorable efficacy and safety profile.